Clinical Trial

A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-04-08
critical Primary endpoint(s) modified 2026-03-27
Trial Details
NCT Number NCT07492381
Lead Sponsor ALPFA Medical
Conditions Prostate Cancer
Enrollment 50 participants
Start Date 2026-04
Primary Completion 2027-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-07